{
    "nct_id": "NCT05490472",
    "official_title": "A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must be able to provide an archived tumor sample\n* Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor\n\n  * Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated\n* Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n* Must have at least 1 measurable lesion per RECIST v1.1\n* Must have adequate organ functions\n* Must be able to swallow and retain orally administered medication\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days\n* Active infection requiring systemic treatment within 7 days\n* Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV\n* Any severe and/or uncontrolled medical conditions\n* left ventricular ejection fraction (LVEF) â‰¤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)\n* QT interval using Fridericia's formula (QTcF) interval >470 msec\n* Experiencing unresolved CTCAE 5.0 Grade >1 toxicities\n* Clinically significant eye disorders",
    "miscellaneous_criteria": ""
}